Company / R&D Expense
Ernexa Therapeutics Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$4.6M
FY2025
5-year range
$26.0K / $10.4M
FY2021-FY2025
Trend
-22.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $10M to $5M over the past 2 years.
Based on SEC 10-K filings.
$5M in FY2025 with a 5-year CAGR of +181.6%.
Declined from $10M to $5M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +181.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +181.6%, indicating consistent growth.
- In FY2025, r&d expense decreased 22.2% year-over-year.
- Peak r&d expense was recorded in FY2023.
- Lowest r&d expense in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.6M | -22.2% |
| FY2024 | $5.9M | -43.0% |
| FY2023 | $10.4M | +39869.2% |
| FY2020 | $26.0K | -63.9% |
| FY2019 | $72.0K | -48.2% |
| FY2018 | $139.0K | - |
| FY2017 | - | - |
| FY2016 | - | - |
| FY2015 | - | - |
| FY2014 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026